Biotechnology - Biotechnology, Gastro-intestinals

Filter

Popular Filters

1 to 25 of 28 results

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex

19-03-2014

German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

17-03-2014

French biotech firm TxCell SA and privately-held Switzerland-headquartered Ferring International have…

BiotechnologyFerring PharmaceuticalsFinancialGastro-intestinalsLicensingOvaSaveTxCell

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Amgen launches collaboration with academia for IBD drug development

15-01-2014

US biotech firm Amgen says it has launched a strategic collaboration with Massachusetts General Hospital…

AmgenBiotechnologyGastro-intestinalsMarkets & MarketingResearch

DMC recommends halt to Actelion’s macitentan Ph III study in digital ulcers

DMC recommends halt to Actelion’s macitentan Ph III study in digital ulcers

02-12-2013

Switzerland-based Actelion this morning announced disappointing news from an independent Data Monitoring…

ActelionBiotechnologyGastro-intestinalsmacitentanResearch

Health Canada backs pediatric Humira for Crohn's

27-08-2013

US drugmaker AbbVie (NYSE: ABBV) says that Health Canada has approved its blockbuster rheumatoid arthritis…

AbbVieBiotechnologyGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

US FDA approves Janssen's Simponi to treat ulcerative colitis

16-05-2013

The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

US gastroenterologists increasingly using biologics to treat Crohn's patients in remission

06-03-2013

Although there have been no significant changes with regard to biologic treatment and Crohn's disease…

AbbVieBiotechnologyCimziaGastro-intestinalsHumiraJanssenMarkets & MarketingNorth AmericaPharmaceuticalRemicadeUCB

Merck Serono spins out sixth company - Calypso Biotech - to focus on gastrointestinal immunological disorders

05-03-2013

German drug major Merck KGaA's (MRK: DE) subsidiary Merck Serono yesterday (March 4) announced the creation…

BiotechnologyCalypso BiotechGastro-intestinalsInflammatory diseasesMerck KGaAMerck SeronoMergers & Acquisitions

Lexicon Pharma updates on clinical pipeline

21-02-2013

US drug developer Lexicon Pharmaceutical (Nasdaq: LXRX) yesterday updated its drug development pipeline,…

BiotechnologyDiabetesGastro-intestinalsLexicon PharmaceuticalsLX1032LX1033LX4211OncologyResearchtelotristat etiprate

FDA approvals for Gattex, Adasuve, Varizig and Tamiflu

27-12-2012

Ahead of the Christmas holiday period, the US Food and Drug Administration announced a number of regulatory…

Anti-viralsBiotechnologyGastro-intestinalsNeurologicalNorth AmericaPharmaceuticalRegulation

Phenex in up to $135 million research collaboration with Janssen

17-12-2012

Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

EU approvals for Viread and Constella; EMA accepts vintafolide MAA

29-11-2012

Among a batch of European Union regulatory news in the last day or two, US biotech firm Gilead Sciences…

AlmirallAnti-viralsBiotechnologyConstellaEndocyteetarfolatideEuropeGastro-intestinalsGilead SciencesIronwood PharmaceuticalsMerck & CoOncologyPharmaceuticalRegulationvintafolideViread

Rhythm expands Series B financing to $33 Million, adding Pfizer Ventures as an investor

27-11-2012

Boston, USA-based biotech firm Rhythm Pharmaceuticals says it has raised an additional $8 million to…

BiotechnologyFinancialGastro-intestinalsIpsenPfizerResearchRhythm PharmaceuticalsRM-131

TxCell raises 12.4 million euros to progress OvaSave

26-11-2012

French biotech firm TxCell SA has raised 12.4 million euros ($16.1 million) in a third financing round.…

BiotechnologyFinancialGastro-intestinalsOvaSaveResearchTxCell

Study finds potential use of ustekinumab for Crohn's disease

18-10-2012

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results…

BiotechnologyGastro-intestinalsJanssenJohnson & JohnsonPharmaceuticalResearchStelara Injectionustekinumab

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb

05-10-2012

USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

Uptake of biosimilars will see Remicade and Humira sales decline in 2017

26-09-2012

The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade) and adalimumab…

BiotechnologyGastro-intestinalsGenericsGlobalHumiraMarkets & MarketingRemicade

US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis

09-09-2012

When evaluating the most important attributes for emerging therapies for Crohn's disease (CD) and ulcerative…

BiotechnologyGastro-intestinalsHumiraMarkets & MarketingNorth AmericaRemicadeSimponi Injectionvedolizumab

Abbott's Humira cleared for Crohn's disease in EU

31-08-2012

The European Commission has approved US health care major Abbott Laboratories' (NYSE: ABT) blockbuster…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyEuropeGastro-intestinalsHumiraPharmaceuticalRegulation

Abbott's Humira gains FDA panel backing for wider use

29-08-2012

The US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee yesterday voted by 15…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

Ferring Pharma gains rights for elobixibat from Albireo

05-07-2012

Swiss drugmaker Ferring Pharmaceuticals has entered into a licensing agreement with Albireo AB, a Sweden-based…

AlbireoBiotechnologyelobixibatFerring PharmaceuticalsGastro-intestinalsLicensingPharmaceutical

Enterologics aims to produce Rx biotherapeutics for GI diseases

05-06-2012

USA-based biotech firm Enterologics (OTCBB: ELGO.OB), which is focussed on the development of live biotherapeutic…

BiotechnologyEnterologicsGastro-intestinalsNorth AmericaResearch

1 to 25 of 28 results

Back to top